0001144204-18-005239.txt : 20180201 0001144204-18-005239.hdr.sgml : 20180201 20180201184114 ACCESSION NUMBER: 0001144204-18-005239 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180130 FILED AS OF DATE: 20180201 DATE AS OF CHANGE: 20180201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oliviero James F III CENTRAL INDEX KEY: 0001434718 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38128 FILM NUMBER: 18568144 MAIL ADDRESS: STREET 1: C/O KERYX BIOPHARMACEUTICALS, INC. STREET 2: 750 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 212-554-4366 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 4 1 tv484690_form4.xml FORM 4 X0306 4 2018-01-30 0 0001651407 Checkpoint Therapeutics, Inc. CKPT 0001434718 Oliviero James F III 2 GANSEVOORT ST, 9TH FLOOR NEW YORK NY 10014 0 1 0 0 CEO and President COMMON STOCK (RESTRICTED) 2018-01-30 4 A 0 325000 0.00 A 1650000 D The shares of restricted stock vest as follows: one-half on January 30, 2020, one-fourth on January 30, 2021 and one-fourth on January 30, 2022. Includes (a) 1,000,000 shares of restricted stock that were granted on October 13, 2015, as previously reported, and are scheduled to vest as follows: (i) 444,444 shares on October 13, 2019; (ii) 222,222 shares on the later of April 1, 2019 or the Company's achievement of market capitalization goals; and (iii) 333,334 shares on the Company's achievement of goals relating to corporate development transactions and/or FDA approval; (b) 325,000 shares of restricted stock that were granted on December 15, 2016, as previously reported, and are scheduled to vest as follows: (i) 243,750 shares on December 15, 2019; and (ii) 81,250 shares on December 15, 2020; and (c) the 325,000 shares of restricted stock that were granted on January 30, 2018, as reported herein. /s/ James F. Oliviero, III 2018-02-01